

MEDIMMUNE INC /DE  
Form 8-K  
July 24, 2006  
UNITED STATES

**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D. C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported)

July 24, 2006

**MedImmune, Inc.**

(Exact name of registrant as specified in its charter)

Delaware

0-19131

52-1555759

(State or other jurisdiction of  
incorporation or organization)

(Commission File No.)

(I.R.S. Employer Identification No.)

One MedImmune Way, Gaithersburg, MD 20878

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (301) 398-0000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

Edgar Filing: MEDIMMUNE INC /DE - Form 8-K

- O Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
- O Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
- O Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
- O Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 2.02. Results of Operations and Financial Condition.**

On July 20, 2006, MedImmune, Inc. (the Company) issued a press release announcing the Company's results for the second quarter and will conduct a previously announced, publicly available conference call to discuss those results. A copy of the Company's press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is hereby furnished in its entirety pursuant to Item 2.02.

**Item 9.01. Financial Statements and Exhibits.**

- (d) Exhibits.

See the attached Exhibit Index.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MedImmune, Inc.**

Date: July 24, 2006  
Atul Saran

By: /s/ Atul Saran

Senior Director, Legal Affairs  
and Assistant Secretary

**EXHIBIT INDEX**

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release dated July 20, 2006, titled MedImmune Reports Second-Quarter and Six-Month Financial Results